Scenarios Included in the Surrogate/Treatment Indicator Comparison

Figshare2015-12-02 更新2026-05-11 收录

数据链接：

https://figshare.com/articles/dataset/_Scenarios_Included_in_the_Surrogate_Treatment_Indicator_Comparison_/1072244 数据链接链接失效反馈

官方服务：

资源简介：

Scenarios Included in the Surrogate/Treatment Indicator Comparison

创建时间：

2015-12-02

Dataset for "What is the validity of microbiological outcomes as a surrogate endpoint compared to clinical outcomes in drug trials for urinary tract infections?"

尿路感染临床试验

替代终点验证

Contains our extraction sheets, study documents (e.g., study protocol), and additional notes/comments on methods used in our study.

NIAID Data Ecosystem60

DataSheet1_The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.docx

肿瘤药物临床评价

替代终点验证

Objective: Due to the initiation of the priority review program in China, many antitumor drugs have been approved for marketing based on phase II clinical trials and short-term surrogate endpoint indi

NIAID Data Ecosystem30

Trial information.

替代终点验证

多发性硬化症临床试验

Background Individual-level surrogacy (ILS) assesses how well a surrogate endpoint predicts treatment effect at the individual level. The paper discusses mutual information (MI) and the likelihood red

NIAID Data Ecosystem10

Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma Suppl data

多发性骨髓瘤临床疗效

替代终点验证

Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma Suppl data

Taylor & Francis Group2024-05-15 更新40

DataSheet_1_Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx

局限期小细胞肺癌放化疗

替代终点验证

PurposeTo investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung

NIAID Data Ecosystem20

Scenarios Included in the Surrogate/Treatment Indicator Comparison

资源简介：

相关数据集